U.S. Markets open in 2 hrs 9 mins
  • S&P Futures

    3,634.25
    +1.50 (+0.04%)
     
  • Dow Futures

    29,968.00
    -30.00 (-0.10%)
     
  • Nasdaq Futures

    12,117.50
    +41.50 (+0.34%)
     
  • Russell 2000 Futures

    1,848.80
    -2.70 (-0.15%)
     
  • Crude Oil

    45.16
    +0.25 (+0.56%)
     
  • Gold

    1,810.50
    +5.90 (+0.33%)
     
  • Silver

    23.38
    +0.08 (+0.32%)
     
  • EUR/USD

    1.1888
    -0.0008 (-0.0713%)
     
  • 10-Yr Bond

    0.8820
    0.0000 (0.00%)
     
  • Vix

    22.08
    -0.58 (-2.56%)
     
  • GBP/USD

    1.3335
    -0.0023 (-0.1747%)
     
  • USD/JPY

    104.4780
    -0.0020 (-0.0019%)
     
  • BTC-USD

    19,192.97
    -73.68 (-0.38%)
     
  • CMC Crypto 200

    380.84
    +11.09 (+3.00%)
     
  • FTSE 100

    6,395.49
    -36.68 (-0.57%)
     
  • Nikkei 225

    26,296.86
    +131.27 (+0.50%)
     

Athenex Announces Participation at the Cowen 40th Annual Health Care Conference

BUFFALO, N.Y., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that management will present at the Cowen 40th Annual Health Care Conference in Boston, Massachusetts on Wednesday, March 4, 2020 at 10:00am Eastern Time. The presentation will be followed by a 30-minute breakout session.

The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.athenex.com.

About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on a P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina. For more information, please visit www.athenex.com.

CONTACTS
Investor Relations:
Tim McCarthy
Managing Director, LifeSci Advisors, LLC
Direct: 212-915-2564

Athenex, Inc.:
Randoll Sze
Chief Financial Officer
Email: RandollSze@athenex.com

Jacqueline Li
Corporate Development and Investor Relations
Email: JacquelineLi@athenex.com